[From NBC, August 31, 2018] “More than one in nine people worldwide who might benefit from a daily pill to minimize their risk of getting HIV are now taking this medicine, a research review suggests.” For more, click here.
HIV prevention pill reaching more people who need it Read More »
[From aidsmap, August 31, 2018] “The US Food and Drug Administration (FDA) has approved two new products containing the next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine. These products are also under review by the European Medicines Agency.” For more, click here.
Two new doravirine pills approved in US Read More »
[From National Institute of Health, August 31, 2018] “An intervention designed to facilitate treatment for HIV and substance use was associated with a 50 percent reduction in mortality for people living with HIV who inject illicit drugs, a study has found. In addition, the people who received the intervention were nearly twice as likely to report
Novel intervention halves rate of death among people living with HIV who inject drugs Read More »
[From CBC, August 30, 2018] “Alberta will be providing universal coverage for PrEP — an HIV-prevention drug that is up to 99 per cent effective at stopping the transmission of the disease — beginning Oct. 1. “It’s about public health. It’s about promoting health and preventing illness,” said Premier Rachel Notley at a surprise announcement during
Alberta gov’t announces universal coverage for HIV-prevention drug PrEP Read More »
[From aidsmap, August 30, 2018] “Chronic pain was reported by a quarter of people living with HIV in an American study published in the Journal of Acquired Immune Deficiency Syndromes. Among people reporting ongoing pain of moderate intensity or worse, individuals who did not receive long-term opioid therapy (LTOT) were at increased risk of missing
